Who Discovered Tadalista 10 Mg Effect On Platelet Aggregation?
There is no specific discovery or scientist credited with “Tadalista 10 mg effect on platelet aggregation” as a unique finding, because this is not a separate scientific discovery tied to the brand name Tadalista.
Key clarification
Tadalista 10 mg is a generic formulation of tadalafil, a PDE5 inhibitor originally developed by pharmaceutical research teams at Eli Lilly and Company researchers in collaboration with Icos Corporation. Tadalafil was later approved and marketed as Cialis.
About platelet aggregation
Research on tadalafil’s effects on platelet function (including platelet aggregation) is part of broader pharmacological studies on PDE5 inhibitors, not specific to the Tadalista 10 mg brand. These studies were conducted by multiple independent academic and clinical researchers after tadalafil’s development, focusing on cardiovascular effects, blood flow, and nitric oxide pathways.
Some studies suggest PDE5 inhibitors may have mild antiplatelet or endothelial effects, but these are secondary findings and not the primary therapeutic action of the drug. The main purpose remains treating erectile dysfunction and sometimes benign prostatic hyperplasia (BPH).
No single individual discovered “Tadalista 10 mg’s effect on platelet aggregation.” Instead, it is part of ongoing scientific research on tadalafil, developed originally by Eli Lilly and Icos researchers and later studied globally by cardiovascular and pharmacology experts.  |
M'inscrire 
Me connecter 
Mot de passe oublié 
Retour au forum
